Bill Gadless’ Post

An incredibly insightful article from Sifted showcasing the strength of the Biotech space across Europe when it comes to VC funding. The UK as a whole is a hotbed for Biotech start-up's and this has been proven over the past 8 years, with the UK generating just shy of $10bn more in funding than our EU counterparts. It's also great to see Scottish based businesses such as Wobble Genomics Ltd generating an incredible $9.9m in funding. Hopefully we can continue on this upward trajectory and provide the foundations for Biotech start-up's to flourish in 2025 and beyond. #biotech #startup #lifescience https://lnkd.in/e-pvrTDZ

From Valuation Confusion to Clarity: Unlocking Biotech's True Potential! 👇 Valuing biotech assets, especially during early drug development, is no easy feat. With less than a 12% chance of progressing from preclinical trials to FDA approval, biotech startups face daunting challenges. Regulatory risks, milestone-based funding, and differing valuation models often create friction between founders and VCs, potentially stalling life-saving innovation. Did you know that common valuation methods, such as risk-adjusted NPV (rNPV), VC models, and real options approaches, can yield significantly different results? This discrepancy often leads to "valuation gaps," where misalignment on a startup's worth prevents crucial funding for promising therapies. Here’s the insight: Founders who understand and articulate their value using the right tools can build bridges with investors, ensuring alignment on both sides. Tools like rNPV adjust for phase-specific risks and allow startups to objectively compare bids on an apples-to-apples basis, while real options valuation captures the flexibility to halt or pivot drug development. How Exigyn Helps: At Exigyn, we’re transforming how biotech startups tackle these challenges. Our solution simplifies complex valuation processes, incorporating real-time data and probabilistic modeling to align both sides of the table. With Exigyn, startups can: Precisely model phase-specific risks and cash flow scenarios. Standardize milestone comparisons across bids. Unlock insights that foster transparent negotiations with VCs. Let’s bring life-saving therapies to market faster by resolving valuation gaps and strengthening partnerships. Together, we can innovate for impact! learn more at: www.exigyn.com #BiotechValuation #LifeSciences #Innovation #DrugDevelopment #rNPV #RealOptions #VCFunding #BiotechStartups #HealthcareInnovation #FDAApproval #RiskManagement #ClinicalTrials #FinancialModeling #AssetValuation #PharmaIndustry #ValuationTools #StartupFunding #VentureCapital #HealthTech #AIinBiotech #Exigyn #DigitalTransformation #BiotechEcosystem #BiotechInsights #StartupSuccess #FinancialStrategy #Entrepreneurship #BiotechInnovation #HealthcareFinance #PharmaTech

💊 Tracking Venture Capital in Biotech: Trends and Insights for 2024 Drug development is a high-risk, high-reward game, and venture capital (VC) plays a pivotal role in shaping biotech startups. Here's what the latest data reveals: 📈 Investment in Biologic Drugmakers Soars VC funding in biologics has surged over the past three years, with notable contributions from mega-deals like $3B for Altos Labs and $1B for Xaira Therapeutics in drug discovery. 🧬 Therapeutic Focus Biotech funding continues to prioritize cancer and immune diseases, capturing the lion’s share of VC dollars in 2024. 🕒 Shift to Later-Stage Investments VCs are betting big on more mature companies, with investment growth most pronounced in late clinical stages (Phases 2 & 3). 💰 Funding Rounds Are Bigger Than Ever Median values for Series A, B, and C rounds are reaching $100M+, showcasing increasing confidence in high-potential startups. 👥 Top VC Players Firms like RA Capital Management and Arch Ventures are leading the charge, consistently topping funding rounds in biotech year after year. Source : BioPharma Dive 🔗 For a deep dive into venture funding in biotech and access to a regularly updated database, explore the link here: https://lnkd.in/dpXCyNvC #VentureCapital #PrivateEquity #Healthcare #Biotech #Investors ——— I am Alexis, a French pharmacist turned entrepreneur. My company BTHT connects consultants and investors with healthcare experts for calls, advisory and board memberships. For more content like this 👇 Join 16K+ followers by clicking my name + follow 🔔 Join 1.5K+ subscribers to my weekly newsletter 💌

#News: #Lifesciences #investment firm Flagship Pioneering announced Wednesday that it has raised $3.6 billion with an eye toward creating and advancing around 25 new “breakthrough” companies. The raise consists of $2.6 billion that will go into Flagship Fund VIII, along with $1 billion in “side funds” which include sector-specific partnerships, according to the venture capital firm. Flagship will use the money to back companies working in #AI, #humanhealth and #sustainability. The investment strategy is in line with Flagship’s funding priorities in recent years. Founder and CEO Noubar Afeyan in a statement pointed out that in the last six years, the life sciences incubator has “pioneered AI-enabled platforms that transform drug discovery, speed up the drug development process and gain new insights into human health and sustainability.” “By leveraging the power and potential of generative AI, we’re embracing a future in which companies are created and expanded in ways we have not previously experienced, with the prospect for unprecedented impact,” Afeyan said. Read more in BioSpace 👇🏼 https://lnkd.in/e7UYYu4U

Biopharma venture capital trends are shifting, and understanding these changes is crucial for anyone working in the healthcare startup ecosystem. According to PitchBook, in 2025, venture capitalists will focus heavily on biopharma companies advancing to Phase 2 trials. This is because Phase 2 data provides clearer insights into a drug's safety, efficacy, and commercial potential, making it attractive for investments. In 2024, Phase 2 investments totaled $5.2 billion, far outpacing Phase 3 investments, which fell to $1.7 billion. This decline in late-stage investments is largely due to the high financial and operational complexities involved in Phase 3 trials. Strong Phase 2 results are now seen as a gateway to partnerships or licensing deals with major pharmaceutical companies. In a challenging economic climate with rising interest rates, investors are prioritizing startups that demonstrate clear paths to revenue generation or acquisition by Big Pharma. This trend highlights the importance of solid clinical data early in the development process. For those navigating the healthcare startup space, these insights underline the critical need to align with investor priorities and focus on strong, early-stage clinical results. #biotech #healthtech #startup

Market downturns take a toll. For many young biotechnology companies, the past few years have been a lesson in survival, as the evaporation of the sector’s pandemic-era boom brought cutbacks to the investment they so desperately need. A Series A round is often how young biotechs introduce themselves to the world, a financing that’s typically accompanied by an announcement outlining their drug development ambitions. But in the current funding environment, appropriately managing that initial pool of money has become more vital. Downturns focus investor attention on companies’ burn rates, or how quickly they’re spending the funding they’ve raised previously. Such scrutiny may mean prioritizing certain projects over others, deciding to hold off on certain investments or, if a company gets particularly pinched, cutting staff & research.

Surviving Biotech's New Normal: 5 Tips from Industry Experts I recently read this BioPharma Dive piece offering 5 strategies to navigate today’s challenging funding environment: 1️⃣ Drug Platforms Can Still Work, But Need Focus Platform companies must now pursue a lead drug program earlier and target meaningful commercial opportunities. Clear links between the platform and a product are essential, and pharma partnerships are often critical for funding. 2️⃣ Series A Needs to Deliver “Value Inflection” Series A rounds must achieve significant milestones, not just de-risk technology. Larger seed rounds now allow early de-risking, but Series A funding has to generate tangible value and meet higher investor expectations. 3️⃣ Capital Efficient Doesn’t Mean Capital Cheap Downturns force investors to scrutinize burn rates, pushing companies to prioritize projects, delay investments, or even cut staff and research. However, capital efficiency isn’t about spending less—it’s about being smart. Strategic investments, such as supportive studies or manufacturing improvements, can create long-term value, while early planning ensures resources are used effectively. 4️⃣ Cost Discipline Can Be Helpful Limited resources force companies to prioritize critical projects, driving better decisions. Excess funding, however, risks wasteful spending and loss of focus on meaningful progress. 5️⃣ R&D Hypotheses Should Be Regularly Reassessed Successful biotechs often pivot from their initial plans. Continuously evaluating whether a program is still the best course of action—and making hard decisions to stop unproductive projects—can be pivotal for success. full article: https://lnkd.in/ecKkKcuV ------------------------ 👋 I'm Kuba 🤝📈 Partnering with biopharma companies to build exceptional leadership teams in Corporate Strategy, Partnering & Commercial roles Looking for more insights like this? Get in touch 🔔 Hit the bell on my profile for updates 🚩 Follow me ➡️ Connect with me to join the conversation!

After a conversation with a current VC for a biotech startup, their top advice to new entrepreneurs. Is to have experienced advisors on their team. Investors value startups with credible advisors who can guide them towards success. Biotechnology is experiencing a surge in innovation, leading to the development of new vaccines, medicines, and therapies. The landscape of drug development has evolved significantly, fostering collaborative relationships between VC-backed pharma companies and small biotech startups to mitigate risks along the development journey. Studies show that having an investor on board increases the success rate of startups from 18% to 37%. This connection not only enhances success metrics but also boosts market capitalization and acquisition value significantly. Successful partnerships are not limited to the clinical stage but are beneficial even during the preclinical phase, proving advantageous throughout the startup lifecycle, from inception to exit strategies.

🚀 Biotech Startups vs. Pharma Giants: A Perfect Match? 🌍 Biotech innovates, pharma scales—it’s the formula driving today’s biggest breakthroughs. ✨Biotech startups are small but mighty, pushing boundaries with cutting-edge tech. Pharma companies are the powerhouses turning those breakthroughs into global solutions.✨ Who do you think drives more impact—disruptive startups or established pharma players? Or is it all about partnership? Share your take! 👇

Interested in biotech business? Click the weblink below to learn the top 10 biotech companies that recently received the highest funding.